Dermata Therapeutics Inc sees stock surge amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Jan 26
Source: Coinmarketcap
Dermata Therapeutics Inc's stock price increased by 14.22% as it crossed above the 20-day SMA, reflecting positive momentum in the market.
This surge is attributed to broad market strength, with the Nasdaq-100 up 0.14% and the S&P 500 up 0.07%, indicating a favorable environment for growth stocks. The overall market conditions have contributed to investor confidence, allowing Dermata to capitalize on this upward trend.
The strong performance of Dermata Therapeutics Inc suggests that investors are optimistic about the company's future prospects, potentially driven by ongoing developments in its therapeutic pipeline.
Analyst Views on DRMA
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
